Recent Advances in the Management of Refractory IBD
|
|
- Berniece Bennett
- 5 years ago
- Views:
Transcription
1 Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA
2 Outline Introduction Risk stratification Anti-TNFs Vedolizumab Ustekinumab Novel therapeutics Other anti-interleukin agents Tofacitinib (Janus Kinase inhibitor) Ozanimod (S1P1 modulator) Mongerson (anti-smad 7 oligonucleotide) Possible management algorithms
3 1. Colombel JF, et al. Gastroenterology 2017; 152:
4 Goals of IBD Treatment Corticosteroid-free remission Mucosal healing Long term clinical remission (OR=2.8, 95% CI, ) Avoidance of CD-related surgeries (OR=2.22, 95% CI, ) Fewer hospitalizations Improve quality of life 1. Rutgeerts P, et al. Gut. 2007;56: Cintolo M, et al. World J Gastrointest Pathophysiol. 2016; 7: Sokol H, et al. Curr Opin Gastroenterol 2014; 30: Froslie K, et al. Gastroenterol :
5 Treat to Target Assess the following in 6 months after therapy initiation: - Clinical symptoms - Biomarkers (i.e. inflammatory markers, fecal calprotectin) - Endoscopic/mucosal healing is the goal 1. Colombel JF, et al. Gastroenterology 2017; 152:
6 Why is my patient refractory to treatment? Infection CMV, C. diff Concomitant disease Celiac Medications Inadequate dosing of medications Antidrug antibody Strictures Cancer
7 Crohn s disease
8 Crohn s disease: Assess Inflammatory Status 1. Sandborn W, et al. Gastro. 2014;147(3):
9 Crohn s disease: Risk stratification Treatment stratified based on severity and risk of complications 1. Sandborn W, et al. Gastro. 2014;147(3):
10 Crohn s disease: Treatment based on risk stratification 1. Sandborn W, et al. Gastro. 2014;147(3):
11 Anti-TNFs as Induction Therapy for Crohn s Disease Clinical remission Mucosal Healing Infliximab 33-72% 29% Adalimumab 21-43% 27% Anti-TNF naive 36-43% Anti-TNF exposed 21-26% Certolizumab % 10% Anti-TNF naive % Anti-TNF exposed 29.2% 1. Colombel JF, et al. N Engl J Med 2010;362: Lemann M, et al. Gastroenterology 2006;130: Targan SR, et al. N Engl J Med 1997;337: Hanauer SB, et al. Gastroenterology 2006;130:323-33; quiz Sandborn WJ, et al. Ann Intern Med 2007;146: Watanabe M, et al. J Crohns Colitis 2012;6: Sandborn WJ, et al. Clin Gastroenterol Hepatol 2010;8: e2. 8. Sandborn WJ, et al. N Engl J Med 2007;357: Schreiber S, et al. Gastroenterology 2005;129:
12 Anti-TNFs as Maintenance Therapy (week 30-56) for Crohn s Disease Clinical remission Mucosal Healing Infliximab 42-49% 30% (mono)-44% (combo) Adalimumab 38-81% 24% Certolizumab 48% 14% 1. Colombel JF, et al. N Engl J Med 2010;362: Rutgeerts P, et al. Gastroenterology 2012;142: e2. 3. Hebuterne X, et al. Gut 2013;62:201-8.
13 A brief word on therapeutic drug monitoring (TDM) First biologic is the best chance at treating IBD Optimize medications with therapeutic drug monitoring Benefit: Increased duration of therapy with TDM 1. Vaughn B, et al. Inflamm Bowel Dis. 2014;20(11):
14 1. Khanna R, et al. Aliment Pharmacol Ther. 2013;38:
15 1. Khanna R, et al. Aliment Pharmacol Ther. 2013;38:
16 Selected Targets in IBD Therapy TNFα-inhibitors block systemic inflammation a central cytokine leading to multiple downstream events 1,2 Vedolizumab blocks migration of leukocytes into the gut via α4β7 integrins 1 1. Danese S et al. Nat Rev Gastroenterol Hepatol. 2015;12: Tracey D et al. Pharmacol Ther 2008;117: Adapted from slide courtesy of Dr. Edward V. Loftus, Jr.
17 Vedolizumab in Moderate-Severe CD (GEMINI II) Induction Trial: Week 6 Endpoints Maintenance Trial: Week 52 Endpoints 1. Sandborn WJ et al. N Engl J Med. 2013; 369(8):
18 GEMINI II: Week 52 Outcomes Stratified by Anti-TNF Exposure VDZ/PBO VDZ Q8W VDZ Q4W Percent Clinical CDAI-100 Remission Response Anti-TNF Exposed 1. Sandborn WJ et al. N Engl J Med. 2013; 369(8): Adapted from slide courtesy of Dr. Edward V. Loftus, Jr. Clinical CDAI-100 Remission Response Anti-TNF Naïve
19 Real World Effectiveness of VDZ in Crohn s disease: VICTORY Consortium Retrospective cohort study of 7 US medical centers Majority (90%) previously exposed to anti-tnfs Cumulative remission rates 18% at 6 months 35% at 12 months 54% at 18 months Less likely to achieve clinical remission: Severe disease Active perianal disease Previous/active smoking Previous anti-tnf use Majority of clinical response seen after 6 months of treatment 1. Dulai PS, et al. Am J Gastroenterol. 2016; 111:
20 Selected Targets in IBD Therapy TNFα-inhibitors block systemic inflammation a central cytokine leading to multiple downstream events 1,2 Ustekinumab blocks inflammation produced through IL12/23 1 Vedolizumab blocks migration of leukocytes into the gut via α4β7 integrins 1 1. Danese S et al. Nat Rev Gastroenterol Hepatol. 2015;12: Tracey D et al. Pharmacol Ther 2008;117: Adapted from slide courtesy of Dr. Edward V. Loftus, Jr.
21 1. Feagan BG and Sandborn WJ, et al. NEJM 2016; 375: UNITI Trials: Efficacy of Ustekinumab in Crohn s Disease 100 point reduction in CDAI
22 UNITI-IM: Ustekinumab Maintenance Trial in CD 1. Feagan BG and Sandborn WJ, et al. NEJM 2016; 375:
23 Other therapeutic targets Anti-IL23: MEDI2070 (brazikumab) and risankizumab bind p19 subunit JAK inibitors: - JAK-1 and -3 inhibitor: Tofacitinib - Selective JAK-1 inihibition: Filgotinib and Upadacitinib 1. Danese S et al. Nat Rev Gastroenterol Hepatol. 2015;12: Tracey D et al. Pharmacol Ther 2008;117:244-79
24 Subjects (%) Upadacitinib (ABT-494), a Selective Jak-1 Inhibitor Safe and Effective in Induction of Remission of Crohn s Disease Selective JAK-1 inhibitor Methods Phase II study Inclusion CDAI (moderate-severe) Stool frequency 2.5 daily Abdominal pain 2 SES-CD 6 ( 4 for ileal only disease) 16 week induction Clinical remission (week 16) Stool frequency 1.5 Abdominal pain N= Placebo 37 Endoscopic Remission at Week 12/16 3 mg 6 mg 12 mg 24 mg 24 mg BID BID BID BID QD *P<0.1; **P<0.05; ***P<0.01 Sandborn WJ, et al. Presented at DDW. May Abstract 847h. Slide from Cornerstones 2017 Subjects (%) Methods Endoscopic remission (Week 12 and 16) SES-CD 4 and 2 point decrease Results 220 randomized patients Significant endoscopic remission at doses: 3-, 12- and 24 mg BID Significant clinical remission at 6 mg BID AE with JAK inhibitors: 1 case VZV, 2 GI perforation, 2 cardiovascular events, 1 NMSC N= Placebo 37 Clinical Remission at Week 16 3 mg 6 mg 12 mg 24 mg 24 mg BID BID BID BID QD
25 Filgotinib for Induction of Remission of Moderate-Severe Crohn s Disease FITZROY study (n=174) Filgotinib: once daily oral JAK1 inhibitor Primary endpoint CDAI < 150 at 10 weeks Serious AEs: 9% vs. 4% 200 mg filgotinib v. placebo for 10 weeks Serious infections: 3% vs. 0% Remission Response P-value Filgotinib 47% 59% P= Placebo 23% 41% P= Vermeire S, et al. DDW Late-Breaker May Abstract 812c. Vermeire S, et al. Lancet 2017;389(10066):
26 Targeting Smad7 With Mongersen (GED-0301) Mongersen (GED-0301) is an oral anti-sense oligonucleotide that inhibits Smad7 translation by facilitating degradation of the RNA Smad7 production is inhibited and the TGF-β1 R1 is freed Downstream signal is re-established Suppression of inflammatory gene expression is restored 26 Monteleone G, et al. N Engl J Med. 2015;372: Adapted from slide courtesy of Dr. Edward V. Loftus, Jr.
27 Mongersen in Steroid-Dependent or -Resistant Crohn s Disease Monteleone G et al. N Engl J Med. 2015;372:
28 Ulcerative Colitis
29 Ulcerative colitis Risk stratification Anti-TNFs Anti-integrin: Vedolizumab JAK inhibitor: Tofacitinib S1P1 modulator: Ozanimod
30 Ulcerative colitis: Risk Stratification Treatment stratified based on severity and risk of complications 1. Dassapoulos T, et al. Gastroenterol :
31 Ulcerative colitis: Risk stratification 1. Dassapoulos T, et al. Gastroenterol :
32 Anti-TNFs as Induction Therapy for Ulcerative Colitis Clinical remission Mucosal Healing Infliximab % % Adalimumab 18.5% % Certolizumab 17.9% 45.1% Rutgeerts P, et al. N Engl J Med 2005; 353: Danese S, et al. AP&T 2013; 37(9): Lowenberg M et al. Clin Exp Gastroenterol. 2014;7:53-59
33 Anti-TNFs as Maintenance Therapy (week 30-54) for Ulcerative Colitis Clinical remission Mucosal Healing Infliximab % % Adalimumab 17.3% 25% Golimumab 27.8% 42.4% Rutgeerts P, et al. N Engl J Med 2005; 353: Danese S, et al. AP&T 2013; 37(9): Lowenberg M et al. Clin Exp Gastroenterol. 2014;7:53-59
34 GEMINI I: EFFICACY OF VEDOLIZUMAB IN MODERATE-SEVERE UC Feagan BG et al, N Engl J Med. 2013;369:
35 GEMINI 1: VDZ Efficacy Stratified by Anti-TNF Exposure Patients (%) Clinical response Prior Anti-TNF Failure 3.2 Placebo (N=63) Vedolizumab (N=82) 9.8 Clinical remission Week Clinical response Anti-TNF Naive 6.6 Placebo (N=76) Vedolizumab (N=130) 23.1 Clinical remission Feagan BG et al, N Engl J Med. 2013;369: Adapted from a slide courtesy of Dr. Edward V. Loftus, Jr.
36 GEMINI I: Vedolizumab Maintenance in UC Placebo Vedo Q8wks Vedo Q4wks 10 0 Clinical Remission Mucosal Healing Steroid-Free Remission Feagan BG et al, N Engl J Med. 2013;369: Adapted from a slide courtesy of Dr. Edward V. Loftus, Jr.
37 Maintenance therapy with Oral Tofacitinib Causes Clinical Remission in Patients with UC 1. Sandborn WJ, et al. N Engl J Med :
38 Maintenance therapy with Oral Tofacitinib Causes Endoscopic Remission in Patients with UC 1. Sandborn WJ, et al. N Engl J Med :
39 Safety of Tofacitinib as UC Maintenance Therapy Adverse events, serious adverse events, serious infection rates similar in all treatment arms Overall infections higher, but withdrawal due to AE was lower Zoster signal at 10 BID dose No deaths No intestinal perforations Expected changes in lipids, CK PBO BID Tofa 5 mg BID Tofa 10 mg BID AEs % SAEs Any Infections Serious infections Herpes zoster Malignancy exc NMSC NMSC Withdrawal due to AE Sandborn WJ et al, ECCO 2017 Oral Presentation (OP032) and DDW 2017 Oral Presentation 1080; Sandborn WJ, et al. N Engl J Med : Slide courtesy of Dr. Edward V. Loftus, Jr.
40 Sphingosine-1-phosphate Receptor (S1P1) Modulator: Ozanimod Involved in regulating many immunologic and CV effects Plays a role in lymphocyte trafficking from lymphoid organs S1P1-receptor agonists cause internalization and degradation of S1P1 receptor B and T cells unable to migrate from secondary lymphoid organs Reversible reduction in circulating lymphocytes 1. Sandborn WJ, et al. N Engl J Med :
41 Ozanimod for Induction of Remission (Week 8) in Moderate-Severe UC Phase 2 RCT with oral S1P1 modulator N=197 Ozanimod 1mg v. placebo led to slightly higher rates of CR at week 8 (16% v. 6%, p=0.048) AEs comparable between groups 1. Sandborn WJ, et al. N Engl J Med :
42 Potential Management Algorithm Moderate-Severe Crohn s Disease Anti-TNFs Optimize therapy Vedolizumab Ustekinumab Clinical trials Anti-IL 23 (Brazikumab, Risankizumab) JAK inhibitors (Upadacitinib, Filgotinib) Anti-SMAD 7 (Mongersen)
43 Potential Management Algorithm Moderate-Severe Ulcerative Colitis Anti-TNFs Optimize therapy Surgery Vedolizumab Optimize therapy Tofacitinib Clinical trials S1P1 modulator (ozanimod)
44 Conclusion Remember other causes of ongoing symptoms Optimize first therapy Treat to Target Therapeutic Drug Monitoring Vedolizumab can be considered first-line in UC Ustekinumab can be used in Crohn s disease Many medications are in development Other anti-il-23 agents Tofacitinib (JAK inhibitors) Ozanimod (S1P1 modulator) Mongerson (SMAD 7 antisense)
45 Thank you
Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationNew treatment options in IBD: today and the future. Silvio Danese Istituto Clinico Humanitas, Milan, Italy
New treatment options in IBD: today and the future Silvio Danese Istituto Clinico Humanitas, Milan, Italy Date of preparation: October 2014 GLO/EYV/2014-00010h Overview of the late-stage IBD drug pipeline*
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationSelection and use of the non-anti- TNF biological therapies: Who? When? How?
Selection and use of the non-anti- TNF biological therapies: Who? When? How? Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz Division of Gastroenterology The Icahn School of Medicine
More informationBiologic Therapy for Ulcerative Colitis in 2015
5/6/215 Biologic Therapy for Ulcerative Colitis in 215 John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Bressler B, Marshall JK, et al. Gastroenterology 215;148: 135-58
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationNew and Future Adhesion Molecule Based Therapies in IBD
New and Future Adhesion Molecule Based Therapies in IBD Brian G. Feagan Professor of Medicine, Epidemiology and Biostatistics University of Western Ontario Robarts Clinical Trials London, Ontario, Canada
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationPredicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab.
Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab. Dr Peter Irving Guy s and St Thomas Hospital, London King s College London Response to vedolizumab
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationGionata Fiorino VEDOLIZUMAB E IBD. Un nuovo target terapeutico
Gionata Fiorino VEDOLIZUMAB E IBD Un nuovo target terapeutico Anti cell adhesion molecules Danese S, NEJM 2011 6 Steps leukocyte recruitment Fiorino G. et al. 2010 Vedolizumab Blocks Fewer Biological Pathways
More informationFuture Directions in IBD: Treatments & Approaches JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER APRIL 29, 2018
Future Directions in IBD: Treatments & Approaches JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER APRIL 29, 2018 Why do pharmaceuticals dominate IBD therapy discussions?
More information2nd Nottingham IBD Masterclass, 2017
2nd Nottingham IBD Masterclass, 217 Positioning IL12/IL23 blockade in the Crohn s disease treatment algorithm Prof James Lindsay, Consultant Gastroenterologist, Barts Health NHS Trust Professor in Inflammatory
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationPositioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
More informationSelective leucocyte trafficking inhibitors for treatment of IBD
Selective leucocyte trafficking inhibitors for treatment of IBD Séverine Vermeire MD, PhD Department of Gastroenterology University Hospitals Leuven Belgium Migration of Leucocytes plays a key role in
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationImmunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationTherapies for IBD: the Pipeline. New Therapeutic Agents in IBD
Therapies for IBD: the Pipeline New Therapeutic Agents in IBD William J. Sandborn, MD Professor & Chief, Division of Gastroenterology Director, UCSD IBD Center Budesonide Oral MMX budesonide Rectal budesonide
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationLooking for Answers. IBD Research March 9, Dr. Benjamin Click, MD MS Associate Staff Cleveland Clinic
Looking for Answers IBD Research 2019 March 9, 2019 Dr. Benjamin Click, MD MS Associate Staff Cleveland Clinic Disclosures No relevant financial disclosures There is still no cure for IBD Why me? ETIOLOGY
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationPersonalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment
Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationJoin the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationInflammatory bowel disease: Novel therpaies NZ November 2018
Inflammatory bowel disease: Novel therpaies NZ November 2018 Dr Charlie Lees Consultant Gastroenterologist From the Edinburgh IBD Unit at the Western General Hospital History of treatment for IBD 1950s
More informationUlcerative colitis (UC) is a chronic inflammatory
Induction and Maintenance Therapy with Vedolizumab, a Novel Biologic Therapy for Ulcerative Colitis Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance
More informationVedolizumab: policing leukocyte traffic
Oxford Inflammatory Bowel Disease MasterClass Vedolizumab: policing leukocyte traffic Dr Brian Feagan, London, Canada Vedolizumab : Policing Lymphocyte Traficking Brian G. Feagan Professor of Medicine,
More informationLatest Meds Approved for IBD: What are they and how do they work?
Latest Meds Approved for IBD: What are they and how do they work? JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER SEPT 30, 2018 Brief history of IBD Dr. Burrill Crohn JAMA
More informationThe Refractory Crohn s Disease
The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationAdvances in the development of new biologics in inflammatory bowel disease
INVITED REVIEW Annals of Gastroenterology (2016) 29, 1-6 Advances in the development of new biologics in inflammatory bowel disease Bella Ungar, Uri Kopylov Sheba Medical Center, Tel Hashomer and Sackler
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationCAG Symposium: Management of IBD in 2018
CAG Symposium: Management of IBD in 2018 Waqqas Afif, MD, M. Sc., FRCPC, Associate Professor, Department of Medicine Division of Gastroenterology McGill University Health Center X X X X X CanMEDS Roles
More information5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationCOPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease
Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard
More informationU of Cape Town, South Africa, 10 U of Washington, Seattle, WA,USA, 11 CHRU de Lille, Hôpital Claude Huriez, Lille, France, 12
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Ustekinumab, a Human IL-12/23p40 Monoclonal Antibody, in Moderate-severe Crohn s Disease Refractory to Anti-TNFα: UNITI-1 WJ Sandborn 1,
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationΑπό τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων
Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Conflict of interest By means of this, the speaker confirms that
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationManaging Complications of IBD and Its Therapies David T. Rubin, MD, AGAF
Managing Complications of IBD and Its Therapies David T. Rubin, MD, AGAF Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition University of Chicago Medicine
More informationNew and Emerging Therapies in IBD. Sarah Streett MD, AGAF Clinical Associate Professor of Medicine Stanford University
New and Emerging Therapies in IBD Sarah Streett MD, AGAF Clinical Associate Professor of Medicine Stanford University New and Emerging Therapies in IBD I have no relevant financial disclosures. IBD is
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationWHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY?
WHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY? Siew Ng, Professor MBBS, FRCP, (Lon, Edin), PhD (Lond), AGAF, FHKCP, FHKAM (medicine) Department of Medicine and Therapeutics Chinese University
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationWithdrawal of drug therapy in patients with quiescent Crohn s disease
Withdrawal of drug therapy in patients with quiescent Crohn s disease DR. JEAN-FRÉDÉRIC COLOMBEL DIRECTOR OF THE IBD CENTER, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, USA Withdrawal of drug therapy
More informationI nuovi farmaci biologici: anche nell'anziano?
LE MALATTIE INFIAMMATORIE CRONICHE INTESTINALI NELL ANZIANO I nuovi farmaci biologici: anche nell'anziano? ANNA KOHN (Roma) increasing incidence Jeuring SFG, Inflamm Bowel Dis 2016 IBD Prevalence on December
More informationCrohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?
Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic
More informationOptimizing Therapies for Severe Ulcerative Colitis October 19, 2014
Optimizing Therapies for Severe Ulcerative Colitis October 19, 2014 Ellen J. Scherl, MD, FACP, FACG, AGAF, FASGE, NYSGEF Director Jill Roberts Center for Inflammatory Bowel Disease Jill Roberts IBD Research
More informationBiologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases
Biologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases Walter Reinisch Univ-Klinik für Innere Medizin III Abt. Gastroenterologie & Hepatologie AKH Wien The Biologic s evolution From availabilitydriven
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationIBD Biologicals and Novel therapeutic regimes. Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh
IBD Biologicals and Novel therapeutic regimes Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh 1 Treatment aims in IBD Traditional treatment goals of IBD Control of symptoms?improvement
More informationOnce Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis
Once Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University JKM 2014 Svartz N. Acta Med Scand
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationManaging Crohn s Disease and Ulcerative Colitis
Managing Crohn s Disease and Ulcerative Colitis Samir A. Shah, MD, FACG, FASGE, AGAF Clinical Professor of Medicine, Brown University Chief of Gastroenterology, The Miriam Hospital Gastroenterology Associates,
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationHow to use infliximab?
How to use infliximab? Séverine Vermeire, MD, PhD Division of Gastroenterology University Hospital Gasthuisberg Leuven The how to use infliximab rules Before starting IFX: try optimizing chances for response!
More informationHighlights of DDW 2015: Crohn s disease
Highlights of DDW 2015: Crohn s disease Mark S. Silverberg, MD, PhD, FRCPC Associate Professor of Medicine, University of Toronto Staff Gastroenterologist, Mount Sinai Hospital Senior Investigator, Lunenfeld-Tanenbaum
More informationManagement of Refractory Crohn s Disease
Management of Refractory Crohn s Disease @IBDMD David T. Rubin, MD, FACG, FASGE Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Disclosures Consultant
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More information4/16/2018. Updates in Crohn s Disease. Disclosures. Learning Objectives. Crohn s Disease is Progressive and Destructive
4/16/218 Disclosures Updates in Crohn s Disease David T. Rubin, MD Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition University of Chicago Consultant
More informationTreating to Achieve a Target and Disease Monitoring in 2015: State of the Art
Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art David T. Rubin, MD The Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationDisease Management Strategies for Moderate to Severe IBD in Adults
Disease Management Strategies for Moderate to Severe IBD in Adults Alyssa Parian, MD Assistant Professor of Medicine Johns Hopkins University April 21, 2016 Outline Overview of IBD Treatments (Benefits/Risks)
More informationEmerging Therapies in IBD 2006
Overview Emerging Therapies in IBD 26 David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Describe the unmet needs of therapy in IBD Emerging biologic
More informationResearch Update: Looking for the Answers
Research Update: Looking for the Answers Ted Denson, M.D. Schubert-Martin Inflammatory Bowel Disease Center Research Support: NIH/NIDDK, CCFA, BMRP Figure 2 Approach to Improve Outcomes for our IBD Patients
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationAgenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease
Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) 8 6 4
More informationInflammatory Bowel Disease Drug Therapy 2016
Inflammatory Bowel Disease Drug Therapy 206 David T. Rubin, MD, FACG Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Objectives Outline the goals of
More informationTreatment of Pediatric IBD: What is Different?
Treatment of Pediatric IBD: What is Different? January 13, 2017 Michael Kappelman MD, MPH University of North Carolina at Chapel Hill Overview Is Pediatric IBD the same disease? Treatment considerations
More informationDrug Level Monitoring in IBD. Objectives
Drug Level Monitoring in IBD Corey A. Siegel, MD, MS Director, Dartmouth-Hitchcock IBD Center Associate Professor of Medicine, Geisel School of Medicine at Dartmouth Objectives Review non-biologic drug
More informationBiologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA
Biologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA Overview Indications and Drug Selection Contraindications
More informationAccepted Manuscript. Tofacitinib: A jak of all trades. Kristin E. Burke, Ashwin N. Ananthakrishnan
Accepted Manuscript Tofacitinib: A jak of all trades Kristin E. Burke, Ashwin N. Ananthakrishnan PII: S1542-3565(19)30017-5 DOI: https://doi.org/10.1016/j.cgh.2018.12.044 Reference: YJCGH 56279 To appear
More informationOp#mizing)Management)in)IBD:) Mucosal)Healing)
Op#mizing)Management)in)IBD:) Mucosal)Healing) Vipul&Jairath&MD&PhD& Associate&Professor&of&Medicine,&Epidemiology&and& Biosta=s=cs& Western&University&&& Division&of&Gastroenterology,&& London&Health&Sciences&Network&
More informationFuture Therapies in IBD. William J. Sandborn, M.D. Mayo Clinic, Rochester, Minnesota
Future Therapies in IBD William J. Sandborn, M.D. Mayo Clinic, Rochester, Minnesota Korzenik et al. Nature Reviews Drug Discovery 5, 197 209 (March 2006) doi:10.1038/nrd1986 Therapies for IBD: The Pipeline
More informationCROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM
CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM Crohn's Disease Ulcerative Colitis Steroids x 2 No prior AZA/6-MP Biologic Agent AZA/6-MP STEP-UP MANAGEMENT APPROACH Advantages Patients attain remission
More informationCurrent and Emerging Biologics for Ulcerative Colitis
Gut and Liver, Vol. 9, No. 1, January 2015, pp. 18-27 Review Current and Emerging Biologics for Ulcerative Colitis Sung Chul Park* and Yoon Tae Jeen *Division of Gastroenterology and Hepatology, Department
More informationAssociation Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean Frédéric Colombel, William J. Sandborn, Matthieu Allez, Jean Louis Dupas, Olivier
More informationTherapy for Inflammatory Bowel Disease
Therapy for Inflammatory Bowel Disease Jonathan P. Terdiman, MD Professor of Clinical Medicine Clinical Director, Center for Colitis and Crohn s Disease University of California San Francisco, CA UC: Current
More informationProgress in Inflammatory Bowel Disease
Progress in Inflammatory Bowel Disease Gary R Lichtenstein, MD Director, Center for IBD University of Pennsylvania School of Medicine Hospital of the University of PA Philadelphia, PA Disclosure Research,
More informationLatest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D.
Latest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D. Co-Director, IBD Center Director, Nutrition Support Service UPMC Presbyterian Hospital Division of Gastroenterology,
More informationSYNOPSIS. Issue Date: 25 Oct 2011
SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationEmerging Therapies in IBD: The Future is Bright October 28 th 2017
Emerging Therapies in IBD: The Future is Bright October 28 th 2017 Nirmal Kaur, MD Director, Inflammatory Bowel Disease Center Division of Gastroenterology Henry Ford Health System Disclosures Research
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More information